Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Total Non-Current Liabilities data on record, last reported at $442.6 million in Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities rose 12.31% year-over-year to $442.6 million; the TTM value through Dec 2024 reached $442.6 million, up 12.31%, while the annual FY2024 figure was $442.6 million, 12.31% up from the prior year.
  • Total Non-Current Liabilities reached $442.6 million in Q4 2024 per MIRM's latest filing, up from $431.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $442.6 million in Q4 2024 and bottomed at $16.7 million in Q1 2020.
  • Average Total Non-Current Liabilities over 5 years is $194.2 million, with a median of $172.4 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 716.57% in 2021, then tumbled 59.11% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $21.1 million in 2020, then soared by 716.57% to $172.4 million in 2021, then crashed by 59.11% to $70.5 million in 2022, then surged by 458.87% to $394.1 million in 2023, then increased by 12.31% to $442.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $442.6 million in Q4 2024, $431.9 million in Q3 2024, and $427.8 million in Q2 2024.